Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck closes in on allergy trifecta with MK-8237 Phase IIb data

This article was originally published in Scrip

Executive Summary

With two new allergy drugs nearing potential US FDA approval, Merck & Co said its sublingual dust mite allergy immunotherapy MK-8237 cut nasal symptoms by up to 49% after 24 weeks of once-daily treatment in a Phase IIb clinical trial.

You may also be interested in...



Second Cellectis CAR-T Therapy On Clinical Hold, Dosing Could Be Issue

A Phase I study for allogeneic therapy UCARTCS1A was put on clinical hold after a patient died. High dosing and double exposure to cyclophosphamide pre-conditioning may have played a role. 

Immunomedics’ ASCENT Confirms Trodelvy’s Efficacy In Triple-Negative Breast Cancer

After accelerated approval in the US in April based on Phase II response rates, the company will seek full approval later this year based on a tripling of progression-free survival in a Phase III trial.

Finance Watch: Up, Up And Away – Biopharma Stocks Keep Rising

Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs. 

Topics

Related Companies

UsernamePublicRestriction

Register

PS140995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel